We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Mutation Identified for Childhood Kidney Cancer

By LabMedica International staff writers
Posted on 13 Jun 2017
The underlying mechanism that causes aneuploidy might be important in understanding cancer risk and not solely having the wrong number of chromosomes in a cell. More...
It is an important development that provides valuable information about the fundamental biology of cancer.

Wilms tumor is a form of kidney cancer that occurs mainly in children and it affects about 1 in 10,000 children, but fortunately is curable in about 90% of cases. Individuals with mosaic variegated aneuploidy (MVA) have cells with the wrong number of chromosomes while some have too many, others have too few and this is known as aneuploidy.

A large team of scientists collaborating with those at The Institute of Cancer Research (London, UK) investigated 20 families with MVA and their genes were analyzed using a technique called exome sequencing. Mutations in a gene called Thyroid Hormone Receptor Interactor 13 (TRIP13) were found. The team identified six individuals with biallelic loss-of-function mutations in TRIP13. All six developed Wilms tumor. Constitutional mosaic aneuploidies, microcephaly, developmental delay and seizures, which are features of MVA syndrome, were more variably present.

The scientists found that TRIP13-mutant patient cells have no detectable TRIP13 and have substantial impairment of the spindle assembly checkpoint (SAC), leading to a high rate of chromosome missegregation. The study also found that not all children with MVA were at high risk. Those with the TRIP13 mutation, and another previously identified mutation called Mitotic Checkpoint Serine/Threonine Kinase B (BUB1B), were at high risk, but children with MVA due to other causes were not.

Nazneen Rahman, PhD, a professor and senior author of the study, said, “This study has been of immediate use to families in providing a reason for why their child developed cancer, and information about risks to other children, which is very rewarding. Equally importantly the study has provided new information about how aneuploidy and cancer are linked, a topic that has been hotly debated and intensively researched for many decades.” The study was published on May 29, 2017, in the journal Nature Genetics.

Related Links:
The Institute of Cancer Research


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.